Related references
Note: Only part of the references are listed.Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature
Matteo Pelosini et al.
ANNALS OF HEMATOLOGY (2008)
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia
Claire Dearden et al.
BLOOD (2008)
Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia
Carlo Visco et al.
BLOOD (2008)
From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity
Paolo Ghia et al.
AUTOIMMUNITY REVIEWS (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients
Milena Elimelakh et al.
HAEMATOLOGICA (2007)
Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology
M. Dungarwalla et al.
ANNALS OF HEMATOLOGY (2007)
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)
C. Karlsson et al.
LEUKEMIA (2007)
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors
Gautam Borthakur et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay et al.
BLOOD (2007)
Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia
Giovanni D'Arena et al.
LEUKEMIA & LYMPHOMA (2007)
Heterogeneous CD52 expression among hematologic neoplasms: Implications for the use of alemtuzumab (CAMPATH-1H)
Scott J. Rodig et al.
CLINICAL CANCER RESEARCH (2006)
Different mechanisms of Campath-1H-mediated depletion for CD4+ and CD8+ T cells in peripheral blood
Hayden Lowenstein et al.
TRANSPLANT INTERNATIONAL (2006)
Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy
Vincenzo Callea et al.
LEUKEMIA & LYMPHOMA (2006)
Hodgkin transformation of chronic lymphocytic leukemia - The M.D. Anderson Cancer Centre Experience
Apostolia-Maria Tsimberidou et al.
CANCER (2006)
The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia
Gulsum Emel Pamuk et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia
Giovanni D'Arena et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Infectious complications of chronic lymphocytic leukemia
PD Wadhwa et al.
SEMINARS IN ONCOLOGY (2006)
Autoimmune complications of chronic lymphocytic leukemia
TJ Hamblin
SEMINARS IN ONCOLOGY (2006)
Immune defects in patients with chronic lymphocytic leukemia
F Ravandi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Tolerability and safety of rituximab (MabThera®)
E Kimby
CANCER TREATMENT REVIEWS (2005)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Richter's transformation of chronic lymphocytic leukemia - The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis
PD Thornton et al.
LEUKEMIA RESEARCH (2005)
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
JC Byrd et al.
BLOOD (2005)
Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine
T Robak et al.
EUROPEAN JOURNAL OF CANCER (2004)
Monoclonal antibodies in the treatment of chronic lymphoid leukemias
T Robak
LEUKEMIA & LYMPHOMA (2004)
Monoclonal antibodies in the treatment of chronic lymphocytic leukemia
NS Liu et al.
MEDICAL ONCOLOGY (2004)
Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma
MJ Kyasa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Richter syndrome in B-cell chronic lymphocytic leukemia
N Nakamura et al.
PATHOLOGY INTERNATIONAL (2003)
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine
GR Goodman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Abnormal T-cell function in B-cell chronic lymphocytic leukaemia
S Scrivener et al.
LEUKEMIA & LYMPHOMA (2003)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
JC Byrd et al.
BLOOD (2003)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Emerging information on the use of rituximab in chronic lymphocytic leukemia
MJ Keating et al.
SEMINARS IN ONCOLOGY (2002)
Rituximab dose-escalation trial in chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia
A Hartkamp et al.
VACCINE (2001)
Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab)
GV Gonzalez-Stawinski et al.
CLINICAL IMMUNOLOGY (2001)
Share Paper
